Accessibility settings

This paper is in the following e-collection/theme issue:

Innovations and Technology in Cancer Care (705) Clinical Information and Decision Making (3878) Cost-Effectiveness and Economics (518) Secondary Use of Clinical Data for Research and Surveillance (654) Economic Evaluations of mHealth Programs and Infrastructures (71)

Published on in Vol 12 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/92253, first published .
Doctor reviews X-ray on tablet, with keyboard and medical equipment in background.

Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study

Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study

Authors of this article:

Iris W A Boot1 Author Orcid Image ;   Anna Louisa Weltin2 Author Orcid Image ;   Ysanne de Graaf1, 3 Author Orcid Image ;   Hubertus J M Vrijhoef1 Author Orcid Image
Article Authors Cited by Tweetations Metrics

Iris W A Boot   1 , MSc ;   Anna Louisa Weltin   2 , MSc ;   Ysanne de Graaf   1, 3 , MSc ;   Hubertus J M Vrijhoef   1 , PhD

1 Panaxea, 's-Hertogenbosch, The Netherlands

2 Department Bio-adaptive Production, Fraunhofer Institute for Production Technology IPT, Aachen, North Rhine-Westphalia, Germany

3 Faculty of Health, Medicine and Life Sciences, Maastricht University, Maatricht, Limburg, The Netherlands

Corresponding Author:

  • Anna Louisa Weltin, MSc
  • Department Bio-adaptive Production
  • Fraunhofer Institute for Production Technology IPT
  • Steinbachstraße 17
  • Aachen, North Rhine-Westphalia 52074
  • Germany
  • Phone: 49 241 8904-236
  • Email: louisa.weltin@ipt.fraunhofer.de